Endocrine Society's 9th Annual “T1D Fellows Series” - Microlearning Sessions
(1)
Image For Activity Cover
Availability
On-Demand
13 Courses
Expires on Apr 30, 2023
Cost
$0.00
Credit Offered
No Credit Offered
  • Course Description
  • Learning Objectives
  • Target Audience
  • Faculty and Disclosures
  • Recommended
Type 1 diabetes (T1D) is a lifelong and often complex condition affecting an estimated 1.6 million people in the United States alone. Individuals with T1D are at greater risk of severe hypoglycemia, diabetic ketoacidosis, vascular complications, and diminished quality of life than the general population. The rapidly evolving landscape of T1D management includes pharmacological and technological advances that frequently lead to updated patient care guidelines. Thus, there is an urgent need to provide comprehensive medical education to endocrinology fellows who will enter the workforce and become the next leaders in T1D patient care. These early career endocrinologists will need to be proficient in accurate T1D diagnosis, effective patient-provider communication, latest treatment recommendations, and emerging research.

The Endocrine Society’s 9th annual Endocrine Fellows Series: Type 1 Diabetes Care and Management proposes to meet this need by leveraging the society’s high-quality and expansive membership and proven commitment to fellows. Learners will have exclusive access to state-of-the-art blended learning resources as well as unique in-person sessions offering representative-led device demonstrations and conversations with leading endocrinology faculty. This immersive conference is a transformative experience for fellows and ensures that the next generation of endocrinologists is poised to provide skilled and compassionate care to patients with T1D.

The Endocrine Society's 9th Annual “Type 1 Diabetes Fellows Series” includes 12 on-demand microlearning sessions from experts in the T1D field on topics including: Diagnosing and Understanding Risks of T1D; Screening, Preventing, and Treating Vascular Disease; Addressing Depression in T1D and Challenges across the Lifespan; Nutrition and Exercise in T1D Management; Diabetes, Pregnancy & Breastfeeding; The Pathogenesis of T1D: The Future for Preserving Beta Cell Function; and How to Effectively Bill for a Diabetes Visit.

Upon successful completion these educational initiatives, participants should be better able to:

  • Discuss the prevalence and progression of type 1 diabetes to recognize signs and differentially diagnose diabetes
  • Devise individualized treatment strategies that use new and emerging insulin and non-insulin therapies to manage individuals with type 1 diabetes with and without common comorbid conditions.
  • Incorporate diabetes technologies, including insulin pump therapy and continuous glucose monitoring, into treatment strategies for appropriate individuals with type 1 diabetes and evaluate data from those technologies.
  • Recognize and evaluate individuals with type 1 diabetes for signs of depression and distress using updated guidelines and practice tools.
  • Apply updated knowledge of treatments, practice guidelines, and clinical skills to improve care, long-term outcomes, and sick day management of individuals with type 1 diabetes.
The intended audience for this activity is endocrinologist fellows and early-career clinicians treating patients with type 1 diabetes.

Irl B. Hirsch, MD - Program Co-Chair
University of Washington School of Medicine

Davida F. Kruger, MSN, APN-BC, BC-ADM - Program Co-Chair
Henry Ford Health System

Mark Atkinson, PhD
University of Florida

Robert H. Eckel, MD
University of Colorado

Alison B. Evert, MS, RD, CDE
University of Washington

Carla J. Greenbaum, MD
Benaroya Research Institute

Janet B. McGill, MD, MA, FACE
Washington University in St. Louis

Camille Powe, MD
Massachusetts General Hospital

Michael C. Riddell, PhD
York University

Elizabeth Seaquist, MD
University of Minnesota

Linda M. Siminerio, RN, PhD, CDE
University of Pittsburgh

Jill A. Weissberg-Benchell, PhD, CDE
Northwestern University

Carol Wysham, MD
Rockwood Clinic PS

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

  • Irl B. Hirsch, MD (Co-Chair), has served as a consultant for Abbott Laboratories; and received grant funding from Beta Bionics and Insulet Corporation.
  • Carla J. Greenbaum, MD has served as an advisory board member for Merck, GentiBio; Enthera Sciences, VieloBio, and Altheia Science; as consultant for AstraZeneca; and received grant funding from Bristol-Myers Squibb, Jansen Pharmaceuticals, Pfizer Inc., ProventionBio, and Intrexon.
  • Janet B. McGill, MD, MA, FACE has served as an advisory board member for Bayer Inc., Eli Lilly & Company. Mannkind Corporation, and Novo Nordisk; as a consultant for Boehringer Ingelheim and Gilead; and received grant funding from Dexcom, Medtronic Minimed, Novo Nordisk, and Beta Bionics.

  • Michael C. Riddell, PhD has served as an advisory board member for Eli Lilly & Company and Zealand.

  • Carol Wysham, MD has received grant funding from Abbott Laboratories, Corcept, Eli Lilly & Company, Novo Nordisk, and Regeneron Pharmaceuticals.

The following faculty reported no relevant financial relationships: Mark Atkinson, PhD, Robert H. Eckel, MD, Alison B. Evert, MS, RD, CDE, Camille Powe, MD, Elizabeth Seaquist, MD, Linda Siminerio, PhD, and Jill A. Weissberg-Benchell, PhD, CDE.

The following committee member who planned and reviewed content for this activity reported relevant financial relationships:

  • Davida F. Kruger, MSN, APN-BC, BC-ADM (Co-Chair), has served as an advisory board member for Sanofi, Novo Nordisk, and Modular Medical.

  • Irl B. Hirsch, MD (Co-Chair), has served as a consultant for Abbott Laboratories; and received grant funding from Beta Bionics and Insulet Corporation.

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

This educational activity is supported by educational grant from Abbott Diabetes Care, Dexcom, Lilly USA, Novo Nordisk, Insulet Corporation, Medtronic Diabetes, Provention Bio, and Tandem Diabetes.

   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Android App Download IOS App Download Powered By